Aurinia stocks pipeline with $7M deal for 2 preclinical assets after securing crucial FDA nod

Retrieved on: 2021-08-17 16:07:30

Tags for this article:

Medical specialties

Clinical medicine

B-cell activating factor

Nephritis

Aurinia Pharmaceuticals

Click the tags to see associated articles and topics

Aurinia stocks pipeline with $7M deal for 2 preclinical assets after securing crucial FDA nod. View article details on hiswai:

Excerpt

The Canadian biopharma paid an upfront fee of $6 million and will dish out biobucks and royalties. AUR300 is slated to enter the clinic in the first half of ...

Article found on: www.fiercebiotech.com

View Original Article